How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/afamelanotide-and-nb-uvb-light.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Afamelanotide and NB-UVB Light — Competitive Intelligence Brief

Afamelanotide and NB-UVB Light (Afamelanotide and NB-UVB Light) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Melanocortin receptor agonist. Area: Dermatology.

phase 3 Melanocortin receptor agonist Melanocortin-1 receptor (MC1R) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Afamelanotide and NB-UVB Light (Afamelanotide and NB-UVB Light) — Clinuvel, Inc.. Afamelanotide stimulates melanin production via alpha-melanocyte-stimulating hormone (α-MSH) receptor activation, which is then enhanced by controlled NB-UVB light exposure to increase skin pigmentation and photoprotection.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Afamelanotide and NB-UVB Light TARGET	Afamelanotide and NB-UVB Light	Clinuvel, Inc.	phase 3	Melanocortin receptor agonist	Melanocortin-1 receptor (MC1R)
Vyleesi (Autoinjector)	BREMELANOTIDE	Cosette	marketed	Melanocortin Receptor Agonist	MC1R, MC4R	2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Melanocortin receptor agonist class)

Clinuvel, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Afamelanotide and NB-UVB Light — Competitive Intelligence Brief. https://druglandscape.com/ci/afamelanotide-and-nb-uvb-light. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab